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1. Introduction 
The aging process not only affects the whole body, but also affects individual cells. While 
the age-related changes in the body are popularly recognized as wrinkling of the skin, 
indicating alterations in basement membrane proteins, the processes of cellular aging are 
less well defined. The underlying common theme of cellular aging and whole body aging 
seems to be an increase in oxidative stress. Advanced glycation endproducts (AGEs), which 
are widely accepted to alter basement membrane proteins, also increase oxidative stress. 
Reactive dicarbonyls, such as methylglyoxal (MG), formed during glycolysis and other 
metabolic processes are precursors of AGEs formation and triggers of oxidative stress. MG, 
AGEs and oxidative stress are very likely to induce DNA damage and be at the root of 
cellular aging. Thus, a strategy to prevent an elevation of MG, formation of AGEs and the 
associated oxidative stress has great therapeutic potential to slow the aging process at the 
cellular and the whole body level.  
2. The ageing process  
The process of aging is accepted as an inevitable normal part of the life cycle of each and every 
living organism. Aging can be grossly defined as an overall decline in biological functions. 
Thus, aging involves gradual changes in the body such as reduced immunity, loss of muscle 
strength, stiffening of the arterial wall, loss of elasticity and wrinkling of the skin, and decline 
in memory, all of which result in increasing weakness, risk of developing diseases, and 
ultimately death. These changes take place at the cellular, organ and the whole organism level. 
The whole process of aging unfolds very clearly in species with a long life span such as human 
beings. Cellular aging ultimately translates into whole body aging.  
Hayflick et al. [1] first described cellular senescence in the sixties when they showed that 
normal cells had a limited ability to proliferate in culture. Cellular senescence is believed to 
be initiated by increased cellular stress [2, 3]. Factors contributing to cellular stress and 
aging include dysfunctional telomeres (telomere length) [4, 5], DNA damage [6] and 
mitogenic or oncogenic stimuli and signals [2, 4, 5]. The factors such as age and oxidative 
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stress affect telomere length and telomerase activity which in turn affects cellular senescence 
[4]. Oxidative stress has been shown to damage DNA and affect life span [7-10]. A 
controversial view of cellular senescence is that it is an important protective mechanism 
against transformation of the cell into a malignant phenotype, in which case it would affect 
only mitotically active cells [2, 3]. The molecular mechanisms involved in cellular senescence 
are still being unraveled and will not be considered further in this review. The focus of this 
review will be on MG, a reactive dicarbonyl metabolic intermediate produced in the body, 
AGEs, and oxidative stress, all of which are interrelated and affect cellular as well as whole 
body aging. We will discuss some compounds that can scavenge MG, prevent the formation 
of AGEs (inhibitors) or break the existing AGEs (AGE breakers). 
3. Theories of aging 
Aging has been attributed to a number of different causes which have been presented in the 
form of different theories. These theories are based broadly on two different ideas, one of 
which is programmed life processes (program theories, e.g. Biological Clock theory, Limited 
Number of Proliferation theory), and the other one is of errors, mainly at the DNA and gene 
level, in life processes (error theories, e.g. Disease theory, Cross-linking theory, Rate of 
living theory, Free radical theory). A number of theories of aging are based on the 
combination of these two ideas, i.e. program theories and error theories [11-14].  
Changes at the cellular level ultimately affect the whole body. The cell is a dynamic centre of 
ongoing metabolic activity driven by almost constant use of oxygen. Reasonably, the 
metabolic activity may affect survival or the death of the cell. The ‘Rate of living theory’ 
implicates the role of metabolism in aging, which is based on the observation that animals 
with higher metabolic rates often have shorter life spans. Since the metabolic processes and 
oxygen consumption can also generate oxidative stress, an excess of which is deleterious for 
the cell, the ‘Free radical theory’ of aging has become one of the more popular theories. The 
free radical theory proposes a connection between the metabolic rate and aging through an 
increased oxidative stress generation.  
4. Free radical theory of aging  
Max Rubner proposed the ‘rate of living theory’ early in the 20th century [15]. He observed 
that larger animals, which generally have slower metabolic rates, live longer than smaller 
animals with faster metabolic rates [15]. Even though it is now common knowledge that 
metabolism is associated with the generation of free radicals, it was Commoner et al. [16] 
who discovered the formation of free radicals in vivo. Commoner et al. [16] found that an 
increase in an organism’s metabolic activity can increase the concentration of endogenous 
free radicals. Free radicals are atoms or molecules with an unpaired electron in an orbit, 
making them highly reactive. The high reactivity of free radicals makes them deleterious for 
cells because they react with proteins, lipids, DNA and other biomolecules, and disrupt their 
structure and function. Free radicals can be derived from oxygen mainly in the form of 
superoxide anions (O2-) and hydroxyl radicals (·OH), which are known as reactive oxygen 
species (ROS). Free radicals can also be in the form of highly reactive non-radicals which do 
not have an unpaired electron in their orbit, such as hydrogen peroxide (H2O2). Normally, 
the cells and the body have adequate antioxidant defenses which can neutralize free radicals 
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and prevent the generation of oxidative stress resulting from an excess of free radicals [17-
22]. The formation of free radicals and the function of antioxidants have been nicely 
explained in reviews by Haliwell [20, 21].  
The free radical theory of aging was proposed by Denham Harman in 1956 [23]. The free 
radical theory of aging attributes the aging process to cumulative cellular damage inflicted by 
the reaction of free radicals with key functional cellular and tissue constituents resulting in 
impaired function, disease and death [23]. The discovery of an antioxidant enzyme, 
superoxide dismutase (SOD) [24], which plays a key role to eliminate superoxide anion levels, 
provided some validity to the free radical theory, which was not initially accepted by many.  
The mitochondrial respiratory chain is a major source of free radicals, mainly in the form of 
superoxide anions, which cause damage to the mitochondria and reduce life span [25, 26]. 
The damage inflicted by ROS, especially to DNA [7], rather than the metabolic rate, showed 
a greater correlation with life span [8]. Damage to DNA was formulated into the somatic 
mutation theory, which states that genetic mutations caused by an excess of free radicals 
could lead to accelerated aging [7, 9, 10].  
The fact that increased production of ROS in the mitochondria can reduce life span was 
supported by several studies. Thus, Ku et al., [27] showed that the rates of mitochondrial 
superoxide anion and hydrogen peroxide generation were inversely correlated to maximum 
life span potential when they compared seven different mammalian species with different 
life spans ranging from 3.5 to 30 years. Similarly, ROS production was higher in heart 
mitochondria of the rat, which has a life span of about 4 yrs, than in the long-lived pigeon, 
which has a longer life span of 35 yrs [28]. Theoretically, therefore, if the free radical 
production is diminished, the life span should increase. This has been demonstrated in 
several species. Thus, over expression of SOD and catalase in the worm Caenorhabditis 
elegans (C. Elegans) through age-1 alleles, increases their oxidative defenses and life span by 
65% longer on average [29, 30]. Increased activity of SOD and reduced oxidative stress in the 
transgenic Drosophila (Drosophila melanogaster) flies also slows the aging process and results 
in a longer life [31, 32]. Also, over expression of catalase in the peroxisome, the mitochondria 
or the nucleus in transgenic mice, reduced oxidative damage, hydrogen peroxide 
production, and delayed the development of cardiac pathology and cataract formation 
along with an average increase of 5.5 months in the life span [33]. The observation that long-
lived animals have lower levels of antioxidant enzymes was explained as being due to a 
lower rate of production of oxygen radicals [34].  
Interestingly, some of the studies in rodents did not produce the expected results. For 
example, the administration of antioxidants [35], or over expression of CuZn SOD and 
catalase in mice [36], or SOD in rats [37], did not increase their life spans. In rodents, one 
reason for the lack of additional protective effects, which are normally associated with an 
increase in antioxidants, could be their ability to synthesize vitamin C [38], which might 
already be providing the required protection. This was verified by knocking out the vitamin 
C synthesizing enzyme, L-gluconolactone oxidase (GLO) in mice, which then have to 
depend on dietary vitamin C [39]. GLO knockout mice had damaged aortic walls when they 
were fed a diet low in vitamin C, which underlined the importance of the constitutive 
antioxidant function of vitamin C in rodents [39]. Thus, studies in rodents do not provide 
unequivocal support for the free radical theory of aging [40]. 
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Another way of increasing free radical production and oxidative stress is by increasing total 
caloric intake, which can be easily done be feeding an excess of glucose. A correlation 
between life span and dietary caloric intake was reported in rats and mice by McCay et al. 
[41]. One quantitative estimate was provided in the study by Weindruch and Walford [42] 
who showed that a 40% reduction in dietary caloric intake extended maximum life span by 
one third. A high dietary caloric intake causes an increased rate of DNA damage [43], due to 
a high metabolic rate which in turn results in higher amounts of superoxide anion, 
hydrogen peroxide and hydroxyl radical formation [44].  
5. Methylglyoxal  
Chemically, MG, or pyruvaldehyde, is a highly reactive electrophilic ǂ,ǃ-dicarbonyl 
compound [45, 46] (Fig. 1). MG has been proposed to be formed mainly during glycolysis, 
through spontaneous nonenzymatic transformation of triose phosphates [45, 47-49] (Fig. 2). 
MG synthase has been proposed to convert the triose phosphate intermediate, 
dihydroxyacetone phosphate (DHAP), into MG, especially when inadequate inorganic 
phosphate is available [50, 51]. Other sources of MG, which are believed to produce lower 
amounts of MG, include intermediates of protein and fatty acid metabolism, such as 
aminoacetone produced from L-threonine and glycine [52, 53], and acetone [54, 55], 
respectively (Fig. 2). Semicarbazide-sensitive amine oxidase (SSAO) catalyzes the 
breakdown of aminoacetone [52, 55, 56], while acetone and acetol mono-oxygenase (AMO) 
converts acetone to acetol and acetol to MG, respectively [54] (Fig. 2). SSAO is found in 
substantial amounts in the vascular smooth muscle cells and the plasma [55].  
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Fig. 1. Structure of methylglyoxal (MG) and three compounds with an ability to bind MG or 
inhibit the formation of advanced glycation endproducts (AGEs) or break formed AGEs. 
These compounds are discussed in this review.  
After MG is formed, it is rapidly degraded to D-lactic acid by the highly efficient and 
ubiquitous glyoxalase system, which consists of two key enzymes, glyoxalase I 
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(lactoylglutathione lyase) and glyoxalase II (hydroxyacylglutathione hydrolase) [57-59] (Fig. 
2). Reduced glutathione (GSH) plays a key role by binding MG and presenting it to 
glyoxalase I. Thus, adequate availability of GSH is important in keeping MG levels low in 
the body. For this reason enzymes involved in the synthesis and recycling of GSH, such as 
glutathione peroxidase and glutathione reductase are also important in the metabolism of 
MG [60-62].  
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Fig. 2. A schematic of key sources and steps of methylglyoxal (MG) formation from 
intermediates of glucose, protein and fat metabolism, and its degradation by the glyoxalase 
enzymes. Abbreviations: AGEs – advanced glycation endproducts; AMO – amine oxidase; 
DHAP – dihydroxacetone phosphate; FA – fatty acid; F-1-P – fructose-1-phosphate; F-1,6-di-
P – fructose-1,6-diphosphate; F-6-P – fructose-6-phosphate; G-3-P – glyceraldehyde-3-
phosphate; G-6-P – glucose-6-phosphate; ROS – reactive oxygen species; SSAO – 
semicarbazide-sensitive acetone/acetol mono-oxygenase; GSH, reduced glutathione. 
Despite the efficient glyoxalase system, MG levels can increase significantly in the plasma 
and different organs such as the aorta and the kidneys [61, 63-66]. We have shown that MG 
levels are elevated in the plasma, aorta and kidney of fructose-fed Sprague-Dawley rats and 
spontaneously hypertensive rats (SHR) [61, 63-65]. Patients with type 1 and type 2 diabetes 
have 2-6 fold higher plasma levels of MG compared to healthy people [67, 68]. MG possibly 
plays a role in the pathogenesis of insulin resistance and type 2 diabetes as shown by several 
in vitro [69-71], and by our recent in vivo study in acute [66] and chronic MG-treated 
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Sprague-Dawley rats [72]. Elevated MG levels are linked to the development of micro-
vascular complications of diabetes such as retinopathy and nephropathy, and other 
conditions such as atherosclerosis and neurodegenerative diseases [73-77]. MG levels are 
high in the cerebrospinal fluid of patients with Alzheimer’s disease [76]. 
6. Advanced glycation endproducts 
Unwanted chemical modification of physiologic constituent molecules of the body, which 
leads to the formation of harmful chemical entities, seems to be an unavoidable part of 
metabolic processes of the body. One type of modification, known as glycation, a 
nonenzymatic reaction, is a serious hazard of excess glucose availability in the body. The 
chemical interaction leading to the formation of AGEs starts when a reducing sugar 
condenses with the amino groups of proteins at their N terminus or on lysyl side chains (ε-
amino groups) [78]. This nonenzymatic glycation involves a series of post-translational 
modifications. Glycation begins with the aldehyde or the ketone carbonyl group of the sugar 
combining with the protein to form an unstable aldimine intermediate or a Schiff base. Later 
on the Schiff base undergoes an Amadori rearrangement to form a stable Amadori product, 
a l-amino-l-deoxyfructose derivative with a stable ketoamine linkage, which can get cyclized 
to form a ring structure [78-80]. The Amadori product can undergo oxidation, degradation 
or rearrangement and form AGEs, a heterogenous group of products. Auto oxidation of 
glucose (Wolff pathway) [81] or of the Schiff bases (Namiki pathway) [82] can lead to 
formation of reactive diacrbonyls, but these pathways which are readily observed at high 
glucose concentrations in vitro, are not predominant in vivo [83]. The Maillard reaction, also 
known as the “browning reaction”, involves oxidation of the glycated product which forms 
a brown coloured product. Glucose, fructose and glucose-6-phosphate are all involved in 
glycation, albeit at different rates of reaction with glucose, the most important contributor, 
reacting at a comparatively slower rate than the other two [6]. Increased glucose levels, as 
seen in diabetic patients, causes more AGEs formation than in healthy people. These AGEs 
affect the normal function of several proteins and enzymes, and are responsible for aging 
[74, 80] and the complications of diabetes such as nephropathy and retinopathy [79]. 
Another way by which the glycation reaction causes damage is through the formation of 
reactive ǂ-dicarbonyl compounds, such as MG, glyoxal and 3-deoxyglucosone (3-DG), when 
the sugar molecule undergoes fragmentation [78].  
MG can also cause AGEs formation [78, 79]. In fact, MG and two other dicarbonyl metabolic 
intermediates, 3-DG and glyoxal, are believed to be major sources of intracellular and 
plasma AGEs formation [79, 84, 85], which are commonly implicated in the aging process. 
Any MG which is not degraded by the glyoxalase system or aldose reductase, reacts non-
enzymatically with arginine or lysine residues of proteins [45] to form irreversible AGEs. 
This glycation is not random, but it depends on the structural configuration and (or) 
physical locations of the target proteins [86, 87]. The AGEs produced by the reaction 
between MG and arginine are hydroimidazolone Nε-(5-hydro-5-methyl-4-imidazolon-2-yl)-
ornithine and argpyrimidine [88], whereas the AGE, Nε-carboxyethyllysine (CEL) [89, 90] is 
formed when MG reacts with lysine. Further crosslinking of these AGEs produces 
fluorescent products such as pentosidine and cross-line, and non-fluorescent ones such as 
argpyrimidine, methylglyoxal-lysine dimer (MOLD), glyoxal-lysine dimer (GOLD) and 
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imidazolones [91, 92]. The presence of these AGEs can be detected immunohistochemically 
in tissues [93].  
7. Methylglyoxal, AGEs, oxidative stress and aging 
The damage inflicted by oxidative stress and the formation of intracellular AGEs likely 
contribute to cellular aging. From this point of view, both increased MG and AGEs would 
cause accelerated cellular aging. MG would be a double-edged sword because it is a potent 
inducer of oxidative stress [17, 62, 94, 95], as discussed below, and it is a major precursor of 
AGEs formation. AGEs also induce oxidative stress.   
8. Methylglyoxal and oxidative stress 
The role of MG in inducing oxidative stress is well established [17]. Several studies have 
helped to develop an integrated view of the multiple pathways activated by MG to increase 
oxidative stress (Fig. 3). The reader is referred to our earlier review on MG and oxidative 
stress [17]. MG increases the formation of superoxide [94, 96-99], hydrogen peroxide and 
peroxynitrite [94, 95, 98, 100], proinflammatory cytokines, such as interleukin 1ǃ (IL-1ǃ) 
[101], interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-ǂ (TNF-ǂ) [67, 101], 
in different cell types such as VSMCs [62, 94, 95], endothelial cells [102], rat kidney 
mesangial cells [97], rat hepatocytes [100], neutrophils [67, 98], platelets [99], cultured neural 
cells from rat hippocampus [101], cultured cortical neurons [103], and SH-SY5Y 
neuroblastoma cells [104]. 
MG has been shown to increase the activity of several prooxidant enzymes such as NADPH 
oxidase [94, 97] (Fig. 3), p38 MAPK [98, 102], and increase the of expression of JNK and 
PPAR-ǂ [104].  
Excess superoxide can react with nitric oxide (NO) to form peroxynitrite (ONOO-) [105]  
(Fig. 3). Peroxynitrite is a strong oxidant and nitrating agent. Because of its oxidizing 
properties, peroxynitrite can damage a wide range of molecules including DNA and 
proteins in cells [105].  
Besides directly increasing free radical production, MG can increase oxidative stress by 
reducing antioxidants (Fig. 3) such as GSH [104, 106, 107], glutathione peroxidase [108], 
glutathione reductase [60, 62, 108, 109], and manganese superoxide dismutase (MnSOD) 
[96], in different cells such as erythrocytes [106, 107], VSMCs [62, 96], and endothelial cells 
[109]. Reduced antioxidants in turn impair the detoxification of MG, increase its  
half-life and set up a vicious cycle to cause further oxidant damage. Glutathione 
peroxidase removes hydrogen peroxide with the help of GSH which in turn is converted 
to oxidized glutathione (GSSG). Glutathione reductase recycles GSSG to GSH [62, 110] 
(Fig. 3).  
An increased production of ROS was also observed in monocytes treated with MG-
modified albumin [111]. Thus, MG induced thrombosis and inflammation by activating 
monocytes, induced apoptosis of neutrophils, and caused platelet-neutrophil aggregates 
[112]. 
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Fig. 3. A schematic of oxidative stress pathways activated by methylglyoxal and advanced 
glycation endproducts and their implication in aging. Abbreviations: AGEs, advanced 
glycation end products; GSH-Px, glutathione peroxidase; GSH-Red, glutathione reductase; 
GSH, reduced glutathione; GSSG, oxidized glutathione; H2O2, hydrogen peroxide; ICAM 1, 
intercellular adhesion molecule 1; IFNǄ, interferon Ǆ; IL1, interleukin 1; JNK, JUN N-
terminal kinase; MG, methylglyoxal; NF-κB, nuclear factor-kappaB; NO, nitric oxide; O2-, 
superoxide anion;  ONOO−, peroxynitrite; p38 MAPK, p38 mitogen activated protein kinase; 
RAGE, receptor for advanced glycation endproduct; SOD, superoxide dismutase; VCAM 1, 
vascular cell adhesion molecule 1. 
Metabolic activity in the mitochondria is at the centre of the free radical theory of aging. 
Mitochondria, which are the major sites of ATP and energy production in the cell, also 
generate about 85% of total intracellular superoxide when electrons escape, mainly from 
complex I and complex III, and react with oxygen [23, 113-116].  
MG increases mitochondrial superoxide production [116, 117]. Treatment of rat aortic 
VSMCs (A-10 cells) with MG (30 μM) significantly increased mitochondrial superoxide 
production by 69.9% compared with untreated cells. The AGEs cross-link breaker, 
alagebrium (50 µM), and SOD mimetic 4-hydroxy-tempo (Tempol, 500 µM) significantly 
decreased MG-induced mitochondrial superoxide production by 57% and 85.8%, 
respectively. Mitochondrial nitrotyrosine formation was also increased by MG [96].  
In in vivo studies elevated MG levels are associated with increased oxidative stress. For 
example, we have shown that in 13 wk old SHR with elevated blood pressure, significantly 
elevated plasma and aortic MG levels are associated with increased levels of superoxide, 
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and significantly reduced GSH levels, glutathione peroxidase, and glutathione reductase 
activities, compared with age-matched Wistar Kyoto (WKY) rats [61]. Similarly, in diabetes 
mellitus and hypertension, increased MG levels are associated with increased oxidative 
stress [61, 65, 67, 68, 118]. 
An excess of MG, CEL and CML indicate carbonyl overload and are associated with 
oxidative stress [73, 79, 119-123].  
Glycated proteins and AGEs also induce oxidative stress (Fig. 3) through several 
mechanisms. AGEs induce production of cytokines and growth factors [124-130]. AGEs bind 
to the receptor for AGEs (RAGE) and scavenger receptors to induce oxidative stress in 
various cells including VSMCs, endothelial cells, and mononuclear phagocytes [128, 131]. In 
endothelial cells AGEs increase expression of vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1), and increase activity of NF-κB to increase 
oxidative stress [126, 132].  
9. Methylglyoxal and aging 
The accumulation of AGEs in extracellular tissue proteins, such as the basement membrane 
and matrix proteins of blood vessels and skin, is a well known phenomenon characteristic of 
aging and age-related diseases. Several studies demonstrate aging associated increase in 
AGEs. Thus, accumulation of AGEs in the vessel walls results in a gradual loss of elasticity, 
which makes older subjects more susceptible to cardiovascular diseases [133, 134]. MG-
induced AGEs, such as CEL and CML, increased with age in human lens and cause cataract 
formation [90]. In a study on 172 subjects serum levels of CML, 8-isoprostanes and C-
reactive protein, which are markers of oxidative stress, were higher in elderly people (>60 
years old) compared with younger people (<45 years old) [135]. One reason why AGEs 
accumulate during the aging process could be due to an age-related decrease in antioxidant 
enzymes. Thus, Mailankot et al. [136] reported that the activity and expression of glyoxalase 
I protein, which is involved in MG degradation, decreased with age in the anterior epithelial 
cells of human lens, which causes an accumulation of MG. Similarly, an age-dependent 
decrease in catalase activity in the skin may be responsible for elevated MG and 
peroxynitrite production [137].  
However, it is doubtful whether extracellular AGEs accumulation plays a causative role in 
aging. On the other hand AGEs formation inside the cell, such as AGE-nucleotides in DNA, 
may contribute to cellular senescence [6, 60, 74, 80]. DNA integrity is an important 
determinant of lifespan and errors in DNA repair would lead to substitutions, deletions, 
insertions, and transpositions of nucleotides, with increased risk of carcinogenesis and 
reduced life span. Animals with a longer lifespan and more efficient DNA repair have 
delayed carcinogenesis [80]. In this regard MG-induced DNA damage can have a more 
direct effect on aging.  
Studies directly implicating MG in the aging process are very few and this is one area where 
there is a knowledge gap. The study by Morcos et al in the worm C. elegans highlights the 
role of MG, glyoxalase I and MG-induced ROS formation in aging and life span [138]. They 
showed that the activity of glyoxalase I was markedly reduced with age resulting in 
accumulation of MG-derived adducts and oxidative stress markers, which further inhibited 
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the expression and the activity of glyoxalase I. Over expression of glyoxalase I decreased 
MG-induced modification of mitochondrial proteins and ROS production, and prolonged 
the lifespan of C. elegans; whereas CeGly knock-out produced the opposite effect [138]. 
Scheckhuber et al. studied the degradation of MG by the glyoxalase system enzymes and its 
effect on growth and lifespan in filamentous ascomycete and a model of aging, Podospora 
anserine (P. anserina) [139]. Using genetic manipulation of the two enzymes of the 
glyoxalase system, they found that up-regulation of both components of the glyoxalase 
system was effective in increasing lifespan in P. anserina. 
Oxidative stress-induced cellular senescence was demonstrated in the study by Sejeresen 
and Rattan [140]. They treated human skin fibroblasts with MG (400 μM), or glyoxal (1.0 
mM), and found the appearance of various senescent phenotypes within three days. These 
phenotypes showed growth arrest, had increased hydrogen peroxide and the glyoxal-
induced AGE, Nε-carboxymethyl lysine (CML) protein levels, and altered SOD and catalase 
antioxidant enzyme activities [140]. Sejeresen and Rattan proposed this model to study 
cellular senescence in vitro [140].  
In this review we have highlighted some important facts that oxidative stress is a major 
factor in the cellular and whole body aging processes, AGEs are strongly associated with 
aging and MG is a major precursor of AGEs formation, and both MG and AGEs are potent 
inducers of oxidative stress. Based on these facts, it is highly likely that MG may have a 
major role in the aging process through induction of oxidative stress as depicted in the 
scheme in Fig. 3. In fact, elevated MG levels may be responsible for causing accelerated 
aging in many tissues and organs of the cardiovascular system, nervous system, and other 
systems of the human body. A strategy to prevent aging should include targeting MG by 
reducing excessive formation, inhibit AGEs formation, and remove excessively formed MG 
and AGEs from the body. 
10. Anti-MG and anti-AGEs compounds 
The deleterious effects of MG and AGEs can be prevented by compounds that can do one or 
all of the following: (i) bind and neutralize reactive aldehydes, especially MG, (ii) prevent 
the formation of AGEs, (iii) neutralize formed AGEs, (iv) break down formed AGEs.  
Considering these multiple ways of preventing the effects of MG or AGEs these compounds 
will be termed as “anti-MG” or “anti-AGE”. Unfortunately, specific anti-MG or anti-AGE 
compounds are not yet available. The ones available are non-specific and have one or more 
other effects, which limits their usefulness. A number of the available compounds happen to 
have anti-MG as well as anti-AGE effects. 
The possible sites at which anti-AGEs and anti-MG drugs can work are shown in Fig. 4, 
which outlines the various stages of AGEs formation.  
Site 1. The first step in glycation is the binding of a sugar to the free amino groups of a protein. 
Drugs that bind to the amino group of proteins, such as aspirin, can prevent the binding of the 
sugar to the amino group. This group of compounds is likely to produce non-specific effects.  
Site 2. Compounds can be used to bind aldose and ketose sugars to neutralize them and 
prevent them from reacting with proteins. E.g. Aminoguanidine reacts with the carbonyl 
group of glucose and prevents AGEs formation.  
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Fig. 4. Stages of formation of advanced glycation endproducts (AGEs) from glycation of 
proteins. Nonenzymatic glycation of protein leads to reversible formation of Schiff bases, 
which lead to further reversible formation of Amadori adducts and ultimate formation of 
stable irreversible AGEs. Solid vertical arrows show these steps which form the classical 
Hodge pathway of AGEs formation. Auto oxidation of glucose (Wolff pathway) or of the 
Schiff base (Namiki pathway) forms reactive dicarbonyls such as methylglyoxal (MG), 
glyoxal (GO) or 3-deoxyglucosone (3-DG) which is mostly seen in vitro, rather than in vivo. 
The dicarbonyls, which are also formed from other metabolic pathways, also contribute 
significantly to AGEs formation, as explained in the text. The various sites at which anti-
AGEs and anti-MG compounds can act are indicated by numbers and discussed in the text. 
Based on the scheme proposed by Khalifah et al. [83] 
Site 3. AGEs and reactive aldehydes also generate reactive oxygen species which adds to 
their damaging effects [17, 141, 142]. Antioxidants such as vitamin C or E [143] and metal 
chelators such as penicillamine [144] can be used to quench ROS and metal ions.   
Site 4. Reactive aldehydes such as MG, glyoxal, glycoaldehyde and glucosones, which are 
formed during nutrient metabolism and AGEs formation, are a major source of AGEs 
formation. Reactive aldehydes can be neutralized by compounds such as aminoguanidine 
[145, 146] and metformin [147, 148]. 
Site 5. Amadori adducts, formed in the intermediate stages of AGEs formation can either be 
quenched by compounds such as aminoguanidine, or degraded enzymatically by enzymes 
such as amadoriase and human fructosamine-3-kinase, which belong to this group [149, 
150]. Amadoriases have not been detected in higher organisms [151, 152]. 
Site 6. The final group of compounds acts on formed AGEs and are therefore, known as 
AGE breakers or cross-link breakers. E.g. phenacylthiazolium bromide (PTB) [153] and 
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alagebrium (previously known as ALT-711), which are thiazolium compounds. AGEs which 
do not have cross-links such as pentosidine [154], GOLD and MOLD [155] will not be 
affected by these drugs.  
Some of the more common compounds with anti-MG or anti-AGEs effects are described 
below. 
Aminoguanidine is one of the popular and widely used AGEs inhibitor [145] and MG 
scavenger. Despite being a guanidine derivative it shares many common properties with 
hydrazine and is classified as a hydrazine [156]. As described above, aminoguanidine acts at 
site 2 as well as site 4 (Fig. 4) meaning that it prevents AGEs formation by combining with 
the carbonyl group of glucose as well as by scavenging reactive dicarbonyls formed during 
various metabolic processes [146]. The inhibitory effect of aminoguanidine is mainly at the 
Amadori stage [83]. Aminoguanidine is not a specific AGEs inhibitor or MG scavenger and 
it has other actions. Aminoguanidine potently inhibits histaminases [157, 158] and prevents 
deamination of histamine and putrescine. Aminoguanidine also inhibits nitric oxide 
synthase (NOS) [159, 160] and prevents the formation of nitric oxide (NO), a dynamic 
signaling molecule in the body [161], from L-arginine. Aminoguanidine also binds to the 
enzyme S-adenosylmethionine decarboxylase and increases synthesis of polyamines such as 
spermidine and spermine from ornithine [162]. Aminoguanidine can also bind pyridoxal 
and cause vitamin B6 deficiency, which in turn can result in adverse reactions to 
aminoguanidine [163]. A number of in vitro and in vivo studies have described the inhibitory 
effects of aminoguanidine on AGEs formation [145, 146, 164-167]. The doses used in vivo 
range from 25 mg/kg/day [145, 166] to 50 mg/kg/day [165] and up to 100 mg/kg/day 
[167]. Thus, aminoguanidine is far from an ideal MG scavenger and AGEs inhibitor. In 
clinical trials aminoguanidine was found to be too toxic for use in patients. Two double-
masked, multiple-dose, placebo-controlled, randomized clinical trials, ACTION I and 
ACTION II [168, 169] investigated the therapeutic potential of aminoguanidine in 
preventing the progression of renal damage in patients with diabetic nephropathy. The 
ACTION I trial involving 690 participants did not show a statistically significant difference 
between the placebo group and the combined aminoguanidine dose groups, even though 
patients treated with aminoguanidine showed a tendency of having a lower risk of doubling 
of serum creatinine [168]. Due to safety concerns and an apparent lack of efficacy, the 
External Safety Monitoring Committee for the ACTION II trial involving 599 participants 
recommended early termination [169]. Patients with diabetes may have impaired red blood 
cell-deformability, which could cause microvascular and kidney damage. A one year trial 
with aminoguanidine and erythropoietin on 12 patients on dialysis restored red blood cell-
deformability to near-normal levels, an effect attributed to inhibition of AGEs formation by 
aminoguanidine [170]. As mentioned earlier the toxic effects of aminoguanidine have 
limited its therapeutic potential. For example, like hydrazine, aminoguanidine may be 
associated with drug-induced systemic lupus erythematosus and abnormal liver function 
tests, and it can cause flu-like syndromes and vasculitis [169]. Aminoguanidine can also 
cause damage to DNA through hydroxyl- and hydrogen peroxide-formation in the presence 
of Fe+3 [171]. 
Metformin is an oral dimethylbiguanide antihyperglycemic agent, which can also inhibit 
AGEs formation [172], through its action in the post-Amadori stages [83, 173]. Metformin 
has also been proposed to have a MG scavenging effect attributed to its guanidino group, 
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which binds with MG to form an inactive product, triazepinone [147, 148, 174, 175]. The 
MG-scavenging effect of metformin resulted in significantly reduced elevated MG levels in 
type 2 diabetes patients treated with high doses of metformin, between 1,500 and 2,500 
mg/day [172]. We have shown that fructose-fed Sprague-Dawley rats had significantly 
elevated serum MG and blood pressure, and increased levels of MG, hydrogen peroxide and 
the MG-derived AGE, CEL, in the aorta, all of which were attenuated by metformin [65]. 
Metformin has been proposed to protect against MG-induced increased atherogenicity of 
low density lipoprotein (LDL) [176]. The use of metformin as a MG scavenger and AGEs 
inhibitor is limited, and hopefully more studies showing its anti-MG, anti-AGEs 
effectiveness will promote its use for this purpose. Metformin can be considered to have a 
good therapeutic potential in this regard since it is already in clinical use for type 2 diabetes 
as an insulin sensitizing agent.   
Pioglitazone, a thiazolidinedione, is a peroxisome proliferator-activated receptor gamma 
(PPARǄ) agonist which acts as an insulin sensitizer and is used in type 2 diabetes. 
Pioglitazone has been proposed to have anti-AGEs effect by inhibiting glycation, AGEs 
formation and protein cross-linking [177, 178]. Studies employing pioglitazone as an anti-
MG or anti-AGEs compound are not forthcoming and more evidence is needed to make 
definitive statements about the therapeutic potential of pioglitazone in this regard. 
N-acetylcysteine (NAC) is a MG scavenging and antioxidant compound [179, 180]. There are 
good reasons for using NAC as an anti-MG compound: NAC can increase GSH levels [181], 
which is an efficient MG scavenger and antioxidant [70, 179, 180], NAC is a cysteine 
containing thiol compound and MG binds with high affinity to cysteine [180, 181], and NAC 
is already used clinically for other conditions such as acetaminophen overdose [179, 181]. 
More studies employing NAC as an anti-MG drug should provide interesting results and 
may help to establish the potential of NAC in this regard. 
A widely used class of antihypertensive drugs has been proposed to have anti-AGE effects. 
Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors 
(ACEIs) have been shown to protect against kidney damage, an effect claimed to be 
independent of their blood pressure lowering action [182-185], but proposed to be due to an 
anti-AGE effect. Clinical trials evaluating AGEs lowering effects of ARBs and ACEIs at 
blood pressure lowering doses can add to the therapeutic utility of these drugs. 
A number of compounds have been investigated for anti-AGE effects in limited studies, but 
have not been widely used as such in experimental studies in animals or humans. These 
compounds include the cycloxygenase inhibitors, aspirin [186-188], ibuprofen [189], 
diclofenac [190],  xanthine derivative, pentoxifylline  [191, 192], which is used for 
claudication in peripheral vascular disease, metal chelators, D-penicillamine [144] and 
desferoxamine [83, 144], thiamine pyrophosphate and pyridoxamine [193-195]. Many more 
studies are necessary for these compounds in order to draw definitive conclusions about 
their anti-MG or anti-AGE effects.  
A number of deglycating enzymes have been discovered, especially in microorganisms, 
which remove the sugar bound to the protein molecule, and possibly provide these bacteria 
with energy substrates derived from glycated products [196]. These enzymes, known as 
amadoriases, include fructosylamine oxidases [197, 198],  fructosamine-3-kinase [149, 150], 
fructoselysine-6-kinase [199], fructoselysine-3-epimerase (FrlC) [200], and glucoselysine-6-
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phosphate deglycase [201]. The use of these enzymes or development of stable analogues for 
deglycation therapy remains speculative . 
A number of AGE inhibitors were synthesized and screened for their AGEs inhibitory 
effects by Rahbar et al. [173, 202, 203]. These are derivatives of aryl ureido and aryl 
carboxaminido phenoxy isobutyric acids and were derived from some known AGEs 
inhibitors. These compounds act at multiple stages of the AGEs formation process. Some of 
these compounds have AGEs breaking properties. More studies are needed for these 
compounds to establish their specificity and safety for therapeutic use.  
11. AGEs breakers 
The AGEs which have undergone cross-linking are very stable products and their 
concentration, especially in long-lived matrix proteins, increases with age. AGEs inhibitors 
are ineffective against formed AGEs and compounds which can break the cross-links are 
required. The AGEs breaker compounds can prove invaluable to slow down the aging 
process, and in the treatment of established stages of diseases such as diabetes, Alzheimer’s, 
atherosclerosis and rheumatoid arthritis.  
The first AGEs breaking compound reported was phenacylthiazolium bromide (PTB) in 
1996. PTB breaks the covalent cross-links of AGEs [204]. Administration of PTB (10 
mg/kg/day, intraperitoneal for 4 wks) reduced the amount of IgG bound to the surface of 
red blood cells in diabetic rats [153]. However, PTB is not stable.  
The search for a stable derivative of PTB resulted in the synthesis of ALT 711 (4,5-
dimethylthiazolium) [205]. ALT 711 (now known as alagebrium) reduced arterial stiffness in 
streptozotocin-induced diabetic rats [205]. In aging rats, ALA (10 mg/kg for 16 weeks) also 
increased glutathione peroxidase and superoxide dismutase activities and reduced oxidative 
stress [206]. Alagebrium improved impaired cardiovascular function in older rhesus 
monkeys [207]. Alagebrium demonstrated promising results and a good safety profile in 
phase 2 clinical trials. In a clinical study involving 93 subjects, 50 yrs and older, with 
evidence of vessel stiffness (pulse pressure ≥60 mm Hg, systolic blood pressure ≥140 mm 
Hg, and large artery compliance ≤1.25 mL/mm Hg), alagebrium (210 mg, once per day for 
56 days) improved arterial compliance [208]. In another group of 13 patients aged 65±2 yrs 
with systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure 
<90 mm Hg), alagebrium (210 mg/kg twice a day for 8 weeks) reduced vascular fibrosis and 
markers of inflammation [209]. Alagebrium (administered for 16 weeks) decreased left 
ventricular mass and improved left ventricular diastolic filling in another trial in 23 patients 
with diastolic heart failure [210, 211].  
However, in a recent study [212] involving 102 patients (aged 62 ± 11 years) with heart 
failure (left ventricular ejection fraction (LVEF ≤0.45), alagebrium (400 mg/day/36 wks) did 
not improve exercise tolerance and systolic dysfunction, and no changes were observed in a 
number of secondary endpoints. Thus, the authors could not verify the claims that 
alagebrium has beneficial effects in systolic heart failure [212].  
Alagebrium has been reported to be a weak inhibitor of thiamine diphosphokinase and is 
unlikely to interfere with thiamine metabolism at therapeutic concentrations [213]. 
However, the authors urge caution when new AGE-crosslink breakers based on thiamine 
are designed, to make sure they are not potent inhibitors of thiamine diphosphokinase. 
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In the studies described above alagebrium has been studied mainly for its chronic effects on 
AGEs as an AGEs breaker. We investigated whether alagebrium also has acute preventive 
effects against the reactive dicarbonyl, MG, in 12 wk old male Sprague-Dawley rats [66]. 
Our results showed that alagebrium also has acute (< 6 h) MG scavenging ability [66]. AGEs 
are formed slowly over a time ranging from 24 h to up to 7 days and more. Therefore, the 
attenuation of MG-induced acute effects (seen within 6 h of MG administration) is most 
likely due to scavenging of MG by alagebrium. Thus, alagebrium significantly attenuated 
the significant increases in MG levels in the plasma, and different organs (measured 2 h after 
administration), and also attenuated MG-induced impaired glucose tolerance and the 
reduced insulin-stimulated glucose uptake by adipose tissue. In an in vitro assay in which 
MG (10 μM) was incubated with or without alagebrium (100 μM) for different times at 37° 
C, alagebrium significantly reduced the amount of detectable MG [66]. Our results strongly 
indicate an acute MG scavenging effect of alagebrium which can add to its AGEs breaking 
ability. More direct evidence of interaction of alagebrium and MG using mass spectrometry 
would be very useful. We have also recently shown that alagebrium significantly attenuated 
the deleterious effects of chronic MG administration for 4 wks on glucose tolerance and 
pancreatic islet ǃ-cell function in male Sprague-Dawley rats [72]. 
In conclusion, MG and AGEs are very likely to be involved in the initiation and or 
progression of the aging process. Commonly available pharmacological compounds to 
investigate these roles of MG and AGEs, such as aminoguanidine, are non-specific, whereas 
some of the newer compounds appear promising in inhibiting AGEs formation at multiple 
steps in the pathway in in vitro studies. However, more in vivo studies are required before 
their therapeutic potential can be established. A more dedicated effort is necessary to 
identify newer anti-MG and anti-AGEs compounds which are more specific and safer before 
more can be done about their therapeutic potential.  
12. References  
[1] Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37: 
614-636; 1965. 
[2] Kovacic, J. C.; Moreno, P.; Hachinski, V.; Nabel, E. G.; Fuster, V. Cellular senescence, 
vascular disease, and aging: Part 1 of a 2-part review. Circulation 123:1650-1660; 
2011. 
[3] Kovacic, J. C.; Moreno, P.; Nabel, E. G.; Hachinski, V.; Fuster, V. Cellular senescence, 
vascular disease, and aging: Part 2 of a 2-part review: Clinical vascular disease in 
the elderly. Circulation 123:1900-1910; 2011. 
[4] Matthews, C.; Gorenne, I.; Scott, S.; Figg, N.; Kirkpatrick, P.; Ritchie, A.; Goddard, M.; 
Bennett, M. Vascular smooth muscle cells undergo telomere-based senescence in 
human atherosclerosis: Effects of telomerase and oxidative stress. Circ. Res. 99:156-
164; 2006. 
[5] Campisi, J.; d'Adda di Fagagna, F. Cellular senescence: When bad things happen to good 
cells. Nat. Rev. Mol. Cell Biol. 8:729-740; 2007. 
[6] Bucala, R.; Model, P.; Cerami, A. Modification of DNA by reducing sugars: A possible 
mechanism for nucleic acid aging and age-related dysfunction in gene expression. 
Proc. Natl. Acad. Sci. U. S. A. 81:105-109; 1984. 
www.intechopen.com
 Pharmacology 
 
696 
[7] Beckman, K. B.; Ames, B. N. The free radical theory of aging matures. Physiol. Rev.78:547-
581; 1998. 
[8] Finkel, T.; Holbrook, N. J. Oxidants, oxidative stress and the biology of ageing. Nature 
408:239-247; 2000. 
[9] Barja, G.; Herrero, A. Oxidative damage to mitochondrial DNA is inversely related to 
maximum life span in the heart and brain of mammals. FASEB J. 14:312-318; 2000. 
[10] Mandavilli, B. S.; Santos, J. H.; Van Houten, B. Mitochondrial DNA repair and aging. 
Mutat. Res. 509:127-151; 2002. 
[11] Vina, J.; Borras, C.; Miquel, J. Theories of ageing. IUBMB Life59:249-254; 2007. 
[12] Weinert, B. T.; Timiras, P. S. Invited review: Theories of aging. J. Appl. Physiol. 95:1706-
1716; 2003. 
[13] Semsei, I. On the nature of aging. Mech. Ageing Dev. 117:93-108; 2000. 
[14] Medvedev, Z. A. An attempt at a rational classification of theories of ageing. Biol. Rev. 
Camb. Philos. Soc. 65:375-398; 1990. 
[15] [Anonymous]. Max rubner--1854-1932. energy physiologist. JAMA 194:86-87; 1965. 
[16] Commoner, B.; Townsend, J.; Pake, G. E. Free radicals in biological materials. Nature 
174:689-691; 1954. 
[17] Desai, K. M.; Wu, L. Free radical generation by methylglyoxal in tissues. Drug Metabol. 
Drug Interact. 23:151-173; 2008. 
[18] McCord, J. M. The evolution of free radicals and oxidative stress. Am. J. Med. 108:652-
659; 2000. 
[19] Cadenas, E. Biochemistry of oxygen toxicity. Annu. Rev. Biochem. 58:79-110; 1989. 
[20] Halliwell, B. Antioxidant defence mechanisms: From the beginning to the end (of the 
beginning). Free Radic. Res. 31:261-272; 1999. 
[21] Halliwell, B. Reactive oxygen species in living systems: Source, biochemistry, and role 
in human disease. Am. J. Med. 91:14S-22S; 1991. 
[22] Gilca, M.; Stoian, I.; Atanasiu, V.; Virgolici, B. The oxidative hypothesis of senescence. J. 
Postgrad. Med. 53:207-213; 2007. 
[23] Harman, D. Aging: A theory based on free radical and radiation chemistry. J. Gerontol. 
11:298-300; 1956. 
[24] McCord, J. M.; Fridovich, I. Superoxide dismutase. an enzymic function for 
erythrocuprein (hemocuprein). J. Biol. Chem. 244:6049-6055; 1969. 
[25] Harman, D. Aging: Overview. Ann. N. Y. Acad. Sci. 928:1-21; 2001. 
[26] Gruber, J.; Schaffer, S.; Halliwell, B. The mitochondrial free radical theory of ageing--
where do we stand? Front. Biosci. 13:6554-6579; 2008. 
[27] Ku, H. H.; Brunk, U. T.; Sohal, R. S. Relationship between mitochondrial superoxide and 
hydrogen peroxide production and longevity of mammalian species. Free Radic. 
Biol. Med. 15:621-627; 1993. 
[28] Herrero, A.; Barja, G. Sites and mechanisms responsible for the low rate of free radical 
production of heart mitochondria in the long-lived pigeon. Mech. Ageing Dev. 98:95-
111; 1997. 
[29] Johnson, T. E.; Tedesco, P. M.; Lithgow, G. J. Comparing mutants, selective breeding, 
and transgenics in the dissection of aging processes of caenorhabditis elegans. 
Genetica 91:65-77; 1993. 
[30] Larsen, P. L. Aging and resistance to oxidative damage in caenorhabditis elegans. Proc. 
Natl. Acad. Sci. U. S. A. 90:8905-8909; 1993. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
697 
[31] Tower, J. Transgenic methods for increasing drosophila life span. Mech. Ageing Dev. 
118:1-14; 2000. 
[32] Arking, R.; Burde, V.; Graves, K.; Hari, R.; Feldman, E.; Zeevi, A.; Soliman, S.; Saraiya, 
A.; Buck, S.; Vettraino, J.; Sathrasala, K.; Wehr, N.; Levine, R. L. Forward and 
reverse selection for longevity in drosophila is characterized by alteration of 
antioxidant gene expression and oxidative damage patterns. Exp. Gerontol. 35:167-
185; 2000. 
[33] Schriner, S. E.; Linford, N. J.; Martin, G. M.; Treuting, P.; Ogburn, C. E.; Emond, M.; 
Coskun, P. E.; Ladiges, W.; Wolf, N.; Van Remmen, H.; Wallace, D. C.; Rabinovitch, 
P. S. Extension of murine life span by overexpression of catalase targeted to 
mitochondria. Science 308:1909-1911; 2005. 
[34] Perez-Campo, R.; Lopez-Torres, M.; Cadenas, S.; Rojas, C.; Barja, G. The rate of free 
radical production as a determinant of the rate of aging: Evidence from the 
comparative approach. J. Comp. Physiol. [B].168:149-158; 1998. 
[35] Huang, T. T.; Carlson, E. J.; Gillespie, A. M.; Shi, Y.; Epstein, C. J. Ubiquitous 
overexpression of CuZn superoxide dismutase does not extend life span in mice. J. 
Gerontol. A Biol. Sci. Med. Sci. 55:B5-9; 2000. 
[36] Perez, V. I.; Van Remmen, H.; Bokov, A.; Epstein, C. J.; Vijg, J.; Richardson, A. The 
overexpression of major antioxidant enzymes does not extend the lifespan of mice. 
Aging Cell. 8:73-75; 2009. 
[37] Mehlhorn, R. J. Oxidants and antioxidanrs in aging. in: Physiological basis of aging and 
geriatrics. Boca Raton, FL:CRC; 2003. 
[38] Linster, C. L.; Van Schaftingen, E. Vitamin C. biosynthesis, recycling and degradation in 
mammals. FEBS J. 274:1-22; 2007. 
[39] Maeda, N.; Hagihara, H.; Nakata, Y.; Hiller, S.; Wilder, J.; Reddick, R. Aortic wall 
damage in mice unable to synthesize ascorbic acid. Proc. Natl. Acad. Sci. U. S. A. 
97:841-846; 2000. 
[40] Muller, F. L.; Lustgarten, M. S.; Jang, Y.; Richardson, A.; Van Remmen, H. Trends in 
oxidative aging theories. Free Radic. Biol. Med. 43:477-503; 2007. 
[41] McCay, C. M.; Crowell, M. F.; Maynard, L. A. The effect of retarded growth upon the 
length of life span and upon the ultimate body size. J. Nutr. 10:63-79; 1935. 
[42] Weindruch, R.; Walford, R. L. The retardation of aging and disease by dietary restriction. 
Springfield IL: Charles C. Thomas.; 1988. 
[43] Simic, M. G.; Bertgold, D. S. Urinary biomarkers of oxidative DNA base damage and human 
caloric intake. in: Biological effects of dietary restriction. New York: Springer-Verlag.; 
1991. 
[44] Szatrowski, T. P.; Nathan, C. F. Production of large amounts of hydrogen peroxide by 
human tumor cells. Cancer Res.51:794-798; 1991. 
[45] Thornalley, P. J. Pharmacology of methylglyoxal: Formation, modification of proteins 
and nucleic acids, and enzymatic detoxification--a role in pathogenesis and 
antiproliferative chemotherapy. Gen. Pharmacol. 27:565-573; 1996. 
[46] Kalapos, M. P. Methylglyoxal in living organisms: Chemistry, biochemistry, toxicology 
and biological implications. Toxicol. Lett. 110:145-175; 1999. 
[47] Phillips, S. A.; Thornalley, P. J. The formation of methylglyoxal from triose phosphates. 
investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 212:101-105; 
1993. 
www.intechopen.com
 Pharmacology 
 
698 
[48] Sato, J.; Wang, Y. M.; van Eys, J. Methylglyoxal formation in rat liver cells. J. Biol. Chem. 
255:2046-2050; 1980. 
[49] Kalapos, M. P. The tandem of free radicals and methylglyoxal. Chem. Biol. Interact. 
171:251-271; 2008. 
[50] Hopper, D. J.; Cooper, R. A. The regulation of escherichia coli methylglyoxal synthase; a 
new control site in glycolysis? FEBS Lett. 13:213-216; 1971. 
[51] Ray, S.; Ray, M. Isolation of methylglyoxal synthase from goat liver. J. Biol. Chem. 
256:6230-6233; 1981. 
[52] Lyles, G. A.; Chalmers, J. The metabolism of aminoacetone to methylglyoxal by 
semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem. 
Pharmacol. 43:1409-1414; 1992. 
[53] Deng, Y.; Yu, P. H. Simultaneous determination of formaldehyde and methylglyoxal in 
urine: Involvement of semicarbazide-sensitive amine oxidase-mediated 
deamination in diabetic complications. J. Chromatogr. Sci. 37:317-322; 1999. 
[54] Casazza, J. P.; Felver, M. E.; Veech, R. L. The metabolism of acetone in rat. J. Biol. Chem. 
259:231-236; 1984. 
[55] Yu, P. H.; Wright, S.; Fan, E. H.; Lun, Z. R.; Gubisne-Harberle, D. Physiological and 
pathological implications of semicarbazide-sensitive amine oxidase. Biochim. 
Biophys. Acta 1647:193-199; 2003. 
[56] Lyles, G. A.; Chalmers, J. Aminoacetone metabolism by semicarbazide-sensitive amine 
oxidase in rat aorta. Biochem. Pharmacol. 49:416-419; 1995. 
[57] Vander Jagt D.L. The glyoxalase system. in: Glutathione: Chemical, biochemical and medical 
aspects - part A. John Wiley & Sons Inc.; 1989. 
[58] Thornalley, P. J. Glyoxalase I--structure, function and a critical role in the enzymatic 
defence against glycation. Biochem. Soc. Trans. 31:1343-1348; 2003. 
[59] Thornalley, P. J. The glyoxalase system in health and disease. Mol. Aspects Med. 14:287-
371; 1993. 
[60] Blakytny, R.; Harding, J. J. Glycation (non-enzymic glycosylation) inactivates 
glutathione reductase. Biochem. J. 288 ( Pt 1):303-307; 1992. 
[61] Wang, X.; Desai, K.; Chang, T.; Wu, L. Vascular methylglyoxal metabolism and the 
development of hypertension. J. Hypertens. 23:1565-1573; 2005. 
[62] Wu, L.; Juurlink, B. H. Increased methylglyoxal and oxidative stress in hypertensive rat 
vascular smooth muscle cells. Hypertension 39:809-814; 2002. 
[63] Wang, X.; Chang, T.; Jiang, B.; Desai, K.; Wu, L. Attenuation of hypertension 
development by aminoguanidine in spontaneously hypertensive rats: Role of 
methylglyoxal. Am. J. Hypertens. 20:629-636; 2007. 
[64] Wang, X.; Desai, K.; Clausen, J. T.; Wu, L. Increased methylglyoxal and advanced 
glycation end products in kidney from spontaneously hypertensive rats. Kidney Int. 
66:2315-2321; 2004. 
[65] Wang, X.; Jia, X.; Chang, T.; Desai, K.; Wu, L. Attenuation of hypertension development 
by scavenging methylglyoxal in fructose-treated rats. J. Hypertens. 26:765-772; 2008. 
[66] Dhar, A.; Desai, K. M.; Wu, L. Alagebrium attenuates acute methylglyoxal-induced 
glucose intolerance in sprague-dawley rats. Br. J. Pharmacol. 159:166-175; 2010. 
[67] Wang, H.; Meng, Q. H.; Gordon, J. R.; Khandwala, H.; Wu, L. Proinflammatory and 
proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 
diabetes mellitus. Clin. Biochem. 40:1232-1239; 2007. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
699 
[68] McLellan, A. C.; Thornalley, P. J.; Benn, J.; Sonksen, P. H. Glyoxalase system in clinical 
diabetes mellitus and correlation with diabetic complications. Clin. Sci. (Lond) 87:21-
29; 1994. 
[69] Jia, X.; Olson, D. J.; Ross, A. R.; Wu, L. Structural and functional changes in human 
insulin induced by methylglyoxal. FASEB J. 20:1555-1557; 2006. 
[70] Jia, X.; Wu, L. Accumulation of endogenous methylglyoxal impaired insulin signaling in 
adipose tissue of fructose-fed rats. Mol. Cell. Biochem.306:133-139; 2007. 
[71] Riboulet-Chavey, A.; Pierron, A.; Durand, I.; Murdaca, J.; Giudicelli, J.; Van Obberghen, 
E. Methylglyoxal impairs the insulin signaling pathways independently of the 
formation of intracellular reactive oxygen species. Diabetes 55:1289-1299; 2006. 
[72] Dhar, A.; Dhar, I.; Jiang, B.; Desai, K. M.; Wu, L. Chronic methylglyoxal infusion by 
minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in 
sprague-dawley rats. Diabetes 60:899-908; 2011. 
[73] Baynes JW Thorpe SR. Role of oxidative stress in diabetic complications: A new 
perspective on an old paradigm. Diabetes 48:1-9; 1999. 
[74] Baynes, J. W. From life to death--the struggle between chemistry and biology during 
aging: The maillard reaction as an amplifier of genomic damage. Biogerontology 
1:235-246; 2000. 
[75] Baynes, J. W.; Thorpe, S. R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. 
Biol. Med. 28:1708-1716; 2000. 
[76] Kuhla, B.; Luth, H. J.; Haferburg, D.; Boeck, K.; Arendt, T.; Munch, G. Methylglyoxal, 
glyoxal, and their detoxification in alzheimer's disease. Ann. N. Y. Acad. Sci. 
1043:211-216; 2005. 
[77] Yu, P. H. Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the 
pathogenesis of alzheimer's disease and vascular dementia. Med. Hypotheses 57:175-
179; 2001. 
[78] Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: A review. 
Diabetologia44:129-146; 2001. 
[79] Vlassara, H.; Bucala, R.; Striker, L. Pathogenic effects of advanced glycosylation: 
Biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 
70:138-151; 1994. 
[80] Baynes, J. W. The role of AGEs in aging: Causation or correlation. Exp. Gerontol. 36:1527-
1537; 2001. 
[81] Wolff, S. P.; Bascal, Z. A.; Hunt, J. V. "Autoxidative glycosylation": Free radicals and 
glycation theory. Prog. Clin. Biol. Res. 304:259-275; 1989. 
[82] Glomb, M. A.; Monnier, V. M. Mechanism of protein modification by glyoxal and 
glycolaldehyde, reactive intermediates of the maillard reaction. J. Biol. Chem. 
270:10017-10026; 1995. 
[83] Khalifah, R. G.; Baynes, J. W.; Hudson, B. G. Amadorins: Novel post-amadori inhibitors 
of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257:251-258; 1999. 
[84] Kilhovd, B. K.; Giardino, I.; Torjesen, P. A.; Birkeland, K. I.; Berg, T. J.; Thornalley, P. J.; 
Brownlee, M.; Hanssen, K. F. Increased serum levels of the specific AGE-compound 
methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. 
Metabolism 52:163-167; 2003. 
[85] Mostafa, A. A.; Randell, E. W.; Vasdev, S. C.; Gill, V. D.; Han, Y.; Gadag, V.; Raouf, A. 
A.; El Said, H. Plasma protein advanced glycation end products, carboxymethyl 
www.intechopen.com
 Pharmacology 
 
700 
cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in 
patients with diabetes. Mol. Cell. Biochem. 302:35-42; 2007. 
[86] Jana, C. K.; Das, N.; Sohal, R. S. Specificity of age-related carbonylation of plasma 
proteins in the mouse and rat. Arch. Biochem. Biophys. 397:433-439; 2002. 
[87] Poggioli, S.; Bakala, H.; Friguet, B. Age-related increase of protein glycation in 
peripheral blood lymphocytes is restricted to preferential target proteins. Exp. 
Gerontol. 37:1207-1215; 2002. 
[88] Shipanova, I. N.; Glomb, M. A.; Nagaraj, R. H. Protein modification by methylglyoxal: 
Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. 
Biochem. Biophys. 344:29-36; 1997. 
[89] Glomb, M. A.; Rosch, D.; Nagaraj, R. H. N(delta)-(5-hydroxy-4,6-dimethylpyrimidine-2-
yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer. J. Agric. Food 
Chem. 49:366-372; 2001. 
[90] Ahmed, M. U.; Brinkmann Frye, E.; Degenhardt, T. P.; Thorpe, S. R.; Baynes, J. W. N-
epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by 
methylglyoxal, increases with age in human lens proteins. Biochem. J. 324 ( Pt 
2):565-570; 1997. 
[91] Chellan, P.; Nagaraj, R. H. Protein crosslinking by the maillard reaction: Dicarbonyl-
derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. 
368:98-104; 1999. 
[92] Konishi, Y.; Hayase, F.; Kato, K. Novel imidazolones compound formed by the 
advanced maillard reaction of 3-deoxyglucosone and arginine residues in proteins. 
Biosci Biotechnol Biochem 58:1953-1955; 1994. 
[93] Uchida, K.; Khor, O. T.; Oya, T.; Osawa, T.; Yasuda, Y.; Miyata, T. Protein modification 
by a maillard reaction intermediate methylglyoxal. immunochemical detection of 
fluorescent 5-methylimidazolone derivatives in vivo. FEBS Lett. 410:313-318; 1997. 
[94] Chang, T.; Wang, R.; Wu, L. Methylglyoxal-induced nitric oxide and peroxynitrite 
production in vascular smooth muscle cells. Free Radic. Biol. Med.  38:286-293; 2005. 
[95] Dhar, A.; Desai, K.; Kazachmov, M.; Yu, P.; Wu, L. Methylglyoxal production in 
vascular smooth muscle cells from different metabolic precursors. Metabolism 
57:1211-1220; 2008. 
[96] Wang, H.; Liu, J.; Wu, L. Methylglyoxal-induced mitochondrial dysfunction in vascular 
smooth muscle cells. Biochem. Pharmacol. In press; 2009. 
[97] Ho, C.; Lee, P. H.; Huang, W. J.; Hsu, Y. C.; Lin, C. L.; Wang, J. Y. Methylglyoxal-
induced fibronectin gene expression through ras-mediated NADPH oxidase 
activation in renal mesangial cells. Nephrology (Carlton) 12:348-356; 2007. 
[98] Ward, R. A.; McLeish, K. R. Methylglyoxal: A stimulus to neutrophil oxygen radical 
production in chronic renal failure? Nephrol. Dial. Transplant. 19:1702-1707; 2004. 
[99] Leoncini, G.; Poggi, M. Effects of methylglyoxal on platelet hydrogen peroxide 
accumulation, aggregation and release reaction. Cell Biochem. Funct. 14:89-95; 1996. 
[100] Kalapos, M. P.; Littauer, A.; de Groot, H. Has reactive oxygen a role in methylglyoxal 
toxicity? A study on cultured rat hepatocytes. Arch. Toxicol. 67:369-372; 1993. 
[101] Di Loreto, S.; Caracciolo, V.; Colafarina, S.; Sebastiani, P.; Gasbarri, A.; Amicarelli, F. 
Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of 
interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. 
Brain Res. 1006:157-167; 2004. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
701 
[102] Akhand, A. A.; Hossain, K.; Mitsui, H.; Kato, M.; Miyata, T.; Inagi, R.; Du, J.; Takeda, 
K.; Kawamoto, Y.; Suzuki, H.; Kurokawa, K.; Nakashima, I. Glyoxal and 
methylglyoxal trigger distinct signals for map family kinases and caspase 
activation in human endothelial cells. Free Radic. Biol. Med. 31:20-30; 2001. 
[103] Kikuchi, S.; Shinpo, K.; Moriwaka, F.; Makita, Z.; Miyata, T.; Tashiro, K. Neurotoxicity 
of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: Synergism 
between glycation and oxidative stress, possibly involved in neurodegenerative 
diseases. J. Neurosci. Res.57:280-289; 1999. 
[104] Amicarelli, F.; Colafarina, S.; Cattani, F.; Cimini, A.; Di Ilio, C.; Ceru, M. P.; Miranda, 
M. Scavenging system efficiency is crucial for cell resistance to ROS-mediated 
methylglyoxal injury. Free Radic. Biol. Med. 35:856-871; 2003. 
[105] Pacher, P.; Beckman, J. S.; Liaudet, L. Nitric oxide and peroxynitrite in health and 
disease. Physiol. Rev. 87:315-424; 2007. 
[106] Nicolay, J. P.; Schneider, J.; Niemoeller, O. M.; Artunc, F.; Portero-Otin, M.; Haik, G.,Jr; 
Thornalley, P. J.; Schleicher, E.; Wieder, T.; Lang, F. Stimulation of suicidal 
erythrocyte death by methylglyoxal. Cell. Physiol. Biochem. 18:223-232; 2006. 
[107] Beard, K. M.; Shangari, N.; Wu, B.; O'Brien, P. J. Metabolism, not autoxidation, plays a 
role in alpha-oxoaldehyde- and reducing sugar-induced erythrocyte GSH 
depletion: Relevance for diabetes mellitus. Mol. Cell. Biochem. 252:331-338; 2003. 
[108] Park, Y. S.; Koh, Y. H.; Takahashi, M.; Miyamoto, Y.; Suzuki, K.; Dohmae, N.; Takio, K.; 
Honke, K.; Taniguchi, N. Identification of the binding site of methylglyoxal on 
glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via 
binding to glutathione binding sites arg 184 and 185. Free Radic. Res. 37:205-211; 
2003. 
[109] Paget, C.; Lecomte, M.; Ruggiero, D.; Wiernsperger, N.; Lagarde, M. Modification of 
enzymatic antioxidants in retinal microvascular cells by glucose or advanced 
glycation end products. Free Radic. Biol. Med. 25:121-129; 1998. 
[110] Juurlink, B. H. Management of oxidative stress in the CNS: The many roles of 
glutathione. Neurotox Res. 1:119-140; 1999. 
[111] Rondeau, P.; Singh, N. R.; Caillens, H.; Tallet, F.; Bourdon, E. Oxidative stresses 
induced by glycoxidized human or bovine serum albumin on human monocytes. 
Free Radic. Biol. Med. 45:799-812; 2008. 
[112] Gawlowski, T.; Stratmann, B.; Stirban, A. O.; Negrean, M.; Tschoepe, D. AGEs and 
methylglyoxal induce apoptosis and expression of mac-1 on neutrophils resulting 
in platelet-neutrophil aggregation. Thromb. Res. 121:117-126; 2007. 
[113] Chance, B.; Oshino, N.; Sugano, T.; Mayevsky, A. Basic principles of tissue oxygen 
determination from mitochondrial signals. Adv. Exp. Med. Biol. 37A:277-292; 1973. 
[114] Turrens, J. F.; Boveris, A. Generation of superoxide anion by the NADH 
dehydrogenase of bovine heart mitochondria. Biochem. J.191:421-427; 1980. 
[115] Turrens, J. F. Superoxide production by the mitochondrial respiratory chain. Biosci. 
Rep. 17:3-8; 1997. 
[116] Rosca, M. G.; Mustata, T. G.; Kinter, M. T.; Ozdemir, A. M.; Kern, T. S.; Szweda, L. I.; 
Brownlee, M.; Monnier, V. M.; Weiss, M. F. Glycation of mitochondrial proteins 
from diabetic rat kidney is associated with excess superoxide formation. Am. J. 
Physiol. Renal Physiol. 289:F420-30; 2005. 
www.intechopen.com
 Pharmacology 
 
702 
[117] Rabbani, N.; Thornalley, P. J. Dicarbonyls linked to damage in the powerhouse: 
Glycation of mitochondrial proteins and oxidative stress. Biochem. Soc. Trans. 
36:1045-1050; 2008. 
[118] Vander Jagt, D. L. Methylglyoxal, diabetes mellitus and diabetic complications. Drug 
Metabol. Drug Interact. 23:93-124; 2008. 
[119] Ando, K.; Beppu, M.; Kikugawa, K.; Nagai, R.; Horiuchi, S. Membrane proteins of 
human erythrocytes are modified by advanced glycation end products during 
aging in the circulation. Biochem. Biophys. Res. Commun. 258:123-127; 1999. 
[120] Li, Y. M.; Steffes, M.; Donnelly, T.; Liu, C.; Fuh, H.; Basgen, J.; Bucala, R.; Vlassara, H. 
Prevention of cardiovascular and renal pathology of aging by the advanced 
glycation inhibitor aminoguanidine. Proc. Natl. Acad. Sci. U. S. A.93:3902-3907; 1996. 
[121] Kilhovd, B. K.; Giardino, I.; Torjesen, P. A.; Birkeland, K. I.; Berg, T. J.; Thornalley, P. J.; 
Brownlee, M.; Hanssen, K. F. Increased serum levels of the specific AGE-compound 
methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. 
Metabolism 52:163-167; 2003. 
[122] Degenhardt, T. P.; Thorpe, S. R.; Baynes, J. W. Chemical modification of proteins by 
methylglyoxal. Cell. Mol. Biol. (Noisy-Le-Grand) 44:1139-1145; 1998. 
[123] Sugimoto, K.; Nishizawa, Y.; Horiuchi, S.; Yagihashi, S. Localization in human diabetic 
peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced 
glycation endproduct. Diabetologia 40:1380-1387; 1997. 
[124] Lo, T. W.; Westwood, M. E.; McLellan, A. C.; Selwood, T.; Thornalley, P. J. Binding and 
modification of proteins by methylglyoxal under physiological conditions. A 
kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, 
and N alpha-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269:32299-
32305; 1994. 
[125] Oya, T.; Hattori, N.; Mizuno, Y.; Miyata, S.; Maeda, S.; Osawa, T.; Uchida, K. 
Methylglyoxal modification of protein. chemical and immunochemical 
characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274:18492-18502; 
1999. 
[126] Kikuchi, S.; Shinpo, K.; Takeuchi, M.; Yamagishi, S.; Makita, Z.; Sasaki, N.; Tashiro, K. 
Glycation--a sweet tempter for neuronal death. Brain Res. Brain Res. Rev. 41:306-323; 
2003. 
[127] Westwood, M. E.; Thornalley, P. J. Induction of synthesis and secretion of interleukin 1 
beta in the human monocytic THP-1 cells by human serum albumins modified with 
methylglyoxal and advanced glycation endproducts. Immunol. Lett. 50:17-21; 1996. 
[128] Wautier, M. P.; Chappey, O.; Corda, S.; Stern, D. M.; Schmidt, A. M.; Wautier, J. L. 
Activation of NADPH oxidase by AGE links oxidant stress to altered gene 
expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280:E685-94; 2001. 
[129] Basta, G.; Lazzerini, G.; Massaro, M.; Simoncini, T.; Tanganelli, P.; Fu, C.; Kislinger, T.; 
Stern, D. M.; Schmidt, A. M.; De Caterina, R. Advanced glycation end products 
activate endothelium through signal-transduction receptor RAGE: A mechanism 
for amplification of inflammatory responses. Circulation 105:816-822; 2002. 
[130] Chen, J.; Brodsky, S. V.; Goligorsky, D. M.; Hampel, D. J.; Li, H.; Gross, S. S.; 
Goligorsky, M. S. Glycated collagen I induces premature senescence-like 
phenotypic changes in endothelial cells. Circ. Res. 90:1290-1298; 2002. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
703 
[131] Thornalley, P. J. Cell activation by glycated proteins. AGE receptors, receptor 
recognition factors and functional classification of AGEs. Cell. Mol. Biol. (Noisy-Le-
Grand) 44:1013-1023; 1998. 
[132] Bierhaus, A.; Chevion, S.; Chevion, M.; Hofmann, M.; Quehenberger, P.; Illmer, T.; 
Luther, T.; Berentshtein, E.; Tritschler, H.; Muller, M.; Wahl, P.; Ziegler, R.; 
Nawroth, P. P. Advanced glycation end product-induced activation of NF-kappaB 
is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46:1481-
1490; 1997. 
[133] Asif, M.; Egan, J.; Vasan, S.; Jyothirmayi, G. N.; Masurekar, M. R.; Lopez, S.; Williams, 
C.; Torres, R. L.; Wagle, D.; Ulrich, P.; Cerami, A.; Brines, M.; Regan, T. J. An 
advanced glycation endproduct cross-link breaker can reverse age-related increases 
in myocardial stiffness. Proc. Natl. Acad. Sci. U. S. A. 97:2809-2813; 2000. 
[134] Scuteri, A. Slowing arterial aging: How far have we progressed? J. Hypertens. 25:509-
510; 2007. 
[135] Uribarri, J.; Cai, W.; Peppa, M.; Goodman, S.; Ferrucci, L.; Striker, G.; Vlassara, H. 
Circulating glycotoxins and dietary advanced glycation endproducts: Two links to 
inflammatory response, oxidative stress, and aging. J. Gerontol. A Biol. Sci. Med. Sci. 
62:427-433; 2007. 
[136] Mailankot, M.; Padmanabha, S.; Pasupuleti, N.; Major, D.; Howell, S.; Nagaraj, R. H. 
Glyoxalase I activity and immunoreactivity in the aging human lens. Biogerontology 
2009. 
[137] Corstjens, H.; Declercq, L.; Hellemans, L.; Sente, I.; Maes, D. Prevention of oxidative 
damage that contributes to the loss of bioenergetic capacity in ageing skin. Exp. 
Gerontol. 42:924-929; 2007. 
[138] Morcos, M.; Du, X.; Pfisterer, F.; Hutter, H.; Sayed, A. A.; Thornalley, P.; Ahmed, N.; 
Baynes, J.; Thorpe, S.; Kukudov, G.; Schlotterer, A.; Bozorgmehr, F.; El Baki, R. A.; 
Stern, D.; Moehrlen, F.; Ibrahim, Y.; Oikonomou, D.; Hamann, A.; Becker, C.; Zeier, 
M.; Schwenger, V.; Miftari, N.; Humpert, P.; Hammes, H. P.; Buechler, M.; 
Bierhaus, A.; Brownlee, M.; Nawroth, P. P. Glyoxalase-1 prevents mitochondrial 
protein modification and enhances lifespan in caenorhabditis elegans. Aging Cell. 
7:260-269; 2008. 
[139] Scheckhuber, C. Q.; Mack, S. J.; Strobel, I.; Ricciardi, F.; Gispert, S.; Osiewacz, H. D. 
Modulation of the glyoxalase system in the aging model podospora anserina: 
Effects on growth and lifespan. Aging (Albany NY) 2:969-980; 2010. 
[140] Sejersen, H.; Rattan, S. I. Dicarbonyl-induced accelerated aging in vitro in human skin 
fibroblasts. Biogerontology 10:203-211; 2009. 
[141] Chappey, O.; Dosquet, C.; Wautier, M. P.; Wautier, J. L. Advanced glycation end 
products, oxidant stress and vascular lesions. Eur. J. Clin. Invest.27:97-108; 1997. 
[142] Gillery, P. Advanced glycation end products (AGEs), free radicals and diabetes. J. Soc. 
Biol. 195:387-390; 2001. 
[143] Kutlu, M.; Naziroglu, M.; Simsek, H.; Yilmaz, T.; Sahap Kukner, A. Moderate exercise 
combined with dietary vitamins C and E counteracts oxidative stress in the kidney 
and lens of streptozotocin-induced diabetic-rat. Int. J. Vitam. Nutr. Res. 75:71-80; 
2005. 
www.intechopen.com
 Pharmacology 
 
704 
[144] Wondrak, G. T.; Cervantes-Laurean, D.; Roberts, M. J.; Qasem, J. G.; Kim, M.; Jacobson, 
E. L.; Jacobson, M. K. Identification of alpha-dicarbonyl scavengers for cellular 
protection against carbonyl stress. Biochem. Pharmacol. 63:361-373; 2002. 
[145] Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. Aminoguanidine 
prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632; 
1986. 
[146] Edelstein, D.; Brownlee, M. Mechanistic studies of advanced glycosylation end product 
inhibition by aminoguanidine. Diabetes 41:26-29; 1992. 
[147] Beisswenger, P.; Ruggiero-Lopez, D. Metformin inhibition of glycation processes. 
Diabetes Metab. 29:6S95-103; 2003. 
[148] Ruggiero-Lopez, D.; Lecomte, M.; Moinet, G.; Patereau, G.; Lagarde, M.; Wiernsperger, 
N. Reaction of metformin with dicarbonyl compounds. possible implication in the 
inhibition of advanced glycation end product formation. Biochem. Pharmacol. 
58:1765-1773; 1999. 
[149] Szwergold, B. S.; Kappler, F.; Brown, T. R. Identification of fructose 3-phosphate in the 
lens of diabetic rats. Science 247:451-454; 1990. 
[150] Delpierre, G.; Rider, M. H.; Collard, F.; Stroobant, V.; Vanstapel, F.; Santos, H.; Van 
Schaftingen, E. Identification, cloning, and heterologous expression of a 
mammalian fructosamine-3-kinase. Diabetes 49:1627-1634; 2000. 
[151] Saxena, A. K.; Saxena, P.; Monnier, V. M. Purification and characterization of a 
membrane-bound deglycating enzyme (1-deoxyfructosyl alkyl amino acid oxidase, 
EC 1.5.3) from a pseudomonas sp. soil strain. J. Biol. Chem. 271:32803-32809; 1996. 
[152] Takahashi, M.; Pischetsrieder, M.; Monnier, V. M. Isolation, purification, and 
characterization of amadoriase isoenzymes (fructosyl amine-oxygen 
oxidoreductase EC 1.5.3) from aspergillus sp. J. Biol. Chem. 272:3437-3443; 1997. 
[153] Vasan, S.; Zhang, X.; Zhang, X.; Kapurniotu, A.; Bernhagen, J.; Teichberg, S.; Basgen, J.; 
Wagle, D.; Shih, D.; Terlecky, I.; Bucala, R.; Cerami, A.; Egan, J.; Ulrich, P. An agent 
cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278; 
1996. 
[154] Grandhee, S. K.; Monnier, V. M. Mechanism of formation of the maillard protein cross-
link pentosidine. glucose, fructose, and ascorbate as pentosidine precursors. J. Biol. 
Chem. 266:11649-11653; 1991. 
[155] Frye, E. B.; Degenhardt, T. P.; Thorpe, S. R.; Baynes, J. W. Role of the maillard reaction 
in aging of tissue proteins. advanced glycation end product-dependent increase in 
imidazolium cross-links in human lens proteins. J. Biol. Chem. 273:18714-18719; 
1998. 
[156] Nilsson, B. O. Biological effects of aminoguanidine: An update. Inflamm. Res. 48:509-
515; 1999. 
[157] SCHULER, W. The inhibition of histaminase. Experientia 8:230-232; 1952. 
[158] Ivy, A. C.; Ivy, E. K.; Karvinen, E.; Lin, T. M. Effect of an histaminase inhibitor 
(aminoguanidine) on the gastric secretory response to exogenous histamine. Am. J. 
Physiol. 186:231-238; 1956. 
[159] Corbett, J. A.; Tilton, R. G.; Chang, K.; Hasan, K. S.; Ido, Y.; Wang, J. L.; Sweetland, M. 
A.; Lancaster, J. R.,Jr; Williamson, J. R.; McDaniel, M. L. Aminoguanidine, a novel 
inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 
41:552-556; 1992. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
705 
[160] Laszlo, F.; Evans, S. M.; Whittle, B. J. Aminoguanidine inhibits both constitutive and 
inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. 
Eur. J. Pharmacol. 272:169-175; 1995. 
[161] Moncada, S.; Palmer, R. M.; Higgs, E. A. Nitric oxide: Physiology, pathophysiology, 
and pharmacology. Pharmacol. Rev. 43:109-142; 1991. 
[162] Stjernborg, L.; Persson, L. Stabilization of S-adenosylmethionine decarboxylase by 
aminoguanidine. Biochem. Pharmacol. 45:1174-1176; 1993. 
[163] Miyata, T.; van Ypersele de Strihou, C. Angiotensin II receptor blockers and 
angiotensin converting enzyme inhibitors: Implication of radical scavenging and 
transition metal chelation in inhibition of advanced glycation end product 
formation. Arch. Biochem. Biophys. 419:50-54; 2003. 
[164] Sajithlal, G. B.; Chithra, P.; Chandrakasan, G. Advanced glycation end products induce 
crosslinking of collagen in vitro. Biochim. Biophys. Acta 1407:215-224; 1998. 
[165] Corman, B.; Duriez, M.; Poitevin, P.; Heudes, D.; Bruneval, P.; Tedgui, A.; Levy, B. I. 
Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. 
Proc. Natl. Acad. Sci. U. S. A. 95:1301-1306; 1998. 
[166] Seyer-Hansen, M.; Andreassen, T. T.; Oxlund, H.; Jorgensen, P. H. The influence of 
aminoguanidine on borohydride reducible collagen cross-links and wound 
strength. Connect. Tissue Res. 26:181-186; 1991. 
[167] Ino-ue, M.; Ohgiya, N.; Yamamoto, M. Effect of aminoguanidine on optic nerve 
involvement in experimental diabetic rats. Brain Res. 800:319-322; 1998. 
[168] Bolton, W. K.; Cattran, D. C.; Williams, M. E.; Adler, S. G.; Appel, G. B.; Cartwright, K.; 
Foiles, P. G.; Freedman, B. I.; Raskin, P.; Ratner, R. E.; Spinowitz, B. S.; Whittier, F. 
C.; Wuerth, J. P.; ACTION I Investigator Group. Randomized trial of an inhibitor of 
formation of advanced glycation end products in diabetic nephropathy. Am. J. 
Nephrol. 24:32-40; 2004. 
[169] Freedman, B. I.; Wuerth, J. P.; Cartwright, K.; Bain, R. P.; Dippe, S.; Hershon, K.; 
Mooradian, A. D.; Spinowitz, B. S. Design and baseline characteristics for the 
aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). 
Control. Clin. Trials 20:493-510; 1999. 
[170] Brown, C. D.; Zhao, Z. H.; Thomas, L. L.; deGroof, R.; Friedman, E. A. Effects of 
erythropoietin and aminoguanidine on red blood cell deformability in diabetic 
azotemic and uremic patients. Am. J. Kidney Dis. 38:1414-1420; 2001. 
[171] Suji, G.; Sivakami, S. DNA damage by free radical production by aminoguanidine. 
Ann. N. Y. Acad. Sci. 1067:191-199; 2006. 
[172] Beisswenger, P. J.; Howell, S. K.; Touchette, A. D.; Lal, S.; Szwergold, B. S. Metformin 
reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes48:198-202; 1999. 
[173] Rahbar, S.; Figarola, J. L. Novel inhibitors of advanced glycation endproducts. Arch. 
Biochem. Biophys. 419:63-79; 2003. 
[174] Baynes, J. W. Role of oxidative stress in development of complications in diabetes. 
Diabetes 40:405-412; 1991. 
[175] Ota, K.; Nakamura, J.; Li, W.; Kozakae, M.; Watarai, A.; Nakamura, N.; Yasuda, Y.; 
Nakashima, E.; Naruse, K.; Watabe, K.; Kato, K.; Oiso, Y.; Hamada, Y. Metformin 
prevents methylglyoxal-induced apoptosis of mouse schwann cells. Biochem. 
Biophys. Res. Commun. 357:270-275; 2007. 
www.intechopen.com
 Pharmacology 
 
706 
[176] Rabbani, N.; Godfrey, L.; Xue, M.; Shaheen, F.; Geoffrion, M.; Milne, R.; Thornalley, P. 
J. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible 
contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60:1973-
1980; 2011. 
[177] Rahbar, S.; Natarajan, R.; Yerneni, K.; Scott, S.; Gonzales, N.; Nadler, J. L. Evidence that 
pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. 
Acta 301:65-77; 2000. 
[178] Hirasawa, Y.; Matsui, Y.; Ohtsu, S.; Yamane, K.; Toyoshi, T.; Kyuki, K.; Sakai, T.; Feng, 
Y.; Nagamatsu, T. Involvement of hyperglycemia in deposition of aggregated 
protein in glomeruli of diabetic mice. Eur. J. Pharmacol. 601:129-135; 2008. 
[179] Millea, P. J. N-acetylcysteine: Multiple clinical applications. Am. Fam. Physician 80:265-
269; 2009. 
[180] Vasdev, S.; Ford, C. A.; Longerich, L.; Parai, S.; Gadag, V.; Wadhawan, S. Aldehyde 
induced hypertension in rats: Prevention by N-acetyl cysteine. Artery 23:10-36; 
1998. 
[181] Lauterburg, B. H.; Corcoran, G. B.; Mitchell, J. R. Mechanism of action of N-
acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats 
in vivo. J. Clin. Invest. 71:980-991; 1983. 
[182] Forbes, J. M.; Cooper, M. E.; Thallas, V.; Burns, W. C.; Thomas, M. C.; Brammar, G. C.; 
Lee, F.; Grant, S. L.; Burrell, L. M.; Jerums, G.; Osicka, T. M. Reduction of the 
accumulation of advanced glycation end products by ACE inhibition in 
experimental diabetic nephropathy. Diabetes 51:3274-3282; 2002. 
[183] Izuhara, Y.; Nangaku, M.; Inagi, R.; Tominaga, N.; Aizawa, T.; Kurokawa, K.; van 
Ypersele de Strihou, C.; Miyata, T. Renoprotective properties of angiotensin 
receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 16:3631-
3641; 2005. 
[184] Miyata, T.; van Ypersele de Strihou, C.; Ueda, Y.; Ichimori, K.; Inagi, R.; Onogi, H.; 
Ishikawa, N.; Nangaku, M.; Kurokawa, K. Angiotensin II receptor antagonists and 
angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced 
glycation end products: Biochemical mechanisms. J. Am. Soc. Nephrol. 13:2478-2487; 
2002. 
[185] Nangaku, M.; Miyata, T.; Sada, T.; Mizuno, M.; Inagi, R.; Ueda, Y.; Ishikawa, N.; 
Yuzawa, H.; Koike, H.; van Ypersele de Strihou, C.; Kurokawa, K. Anti-
hypertensive agents inhibit in vivo the formation of advanced glycation end 
products and improve renal damage in a type 2 diabetic nephropathy rat model. J. 
Am. Soc. Nephrol. 14:1212-1222; 2003. 
[186] Rao, G. N.; Lardis, M. P.; Cotlier, E. Acetylation of lens crystallins: A possible 
mechanism by which aspirin could prevent cataract formation. Biochem. Biophys. 
Res. Commun. 128:1125-1132; 1985. 
[187] Lin, P. P.; Barry, R. C.; Smith, D. L.; Smith, J. B. In vivo acetylation identified at lysine 
70 of human lens alphaA-crystallin. Protein Sci.7:1451-1457; 1998. 
[188] Ajiboye, R.; Harding, J. J. The non-enzymic glycosylation of bovine lens proteins by 
glucosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp. Eye Res. 
49:31-41; 1989. 
[189] Raza, K.; Harding, J. J. Non-enzymic modification of lens proteins by glucose and 
fructose: Effects of ibuprofen. Exp. Eye Res. 52:205-212; 1991. 
www.intechopen.com
Aging: Drugs to Eliminate Methylglyoxal, a Reactive  
Glucose Metabolite, and Advanced Glycation Endproducts 
 
707 
[190] van Boekel, M. A.; van den Bergh, P. J.; Hoenders, H. J. Glycation of human serum 
albumin: Inhibition by diclofenac. Biochim. Biophys. Acta 1120:201-204; 1992. 
[191] Regensteiner, J. G.; Stewart, K. J. Established and evolving medical therapies for 
claudication in patients with peripheral arterial disease. Nat. Clin. Pract. Cardiovasc. 
Med. 3:604-610; 2006. 
[192] Rahbar, S.; Natarajan, R.; Yerneni, K.; Scott, S.; Gonzales, N.; Nadler, J. L. Evidence that 
pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. 
Acta 301:65-77; 2000. 
[193] Booth, A. A.; Khalifah, R. G.; Hudson, B. G. Thiamine pyrophosphate and 
pyridoxamine inhibit the formation of antigenic advanced glycation end-products: 
Comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 220:113-119; 
1996. 
[194] Nagaraj, R. H.; Sarkar, P.; Mally, A.; Biemel, K. M.; Lederer, M. O.; Padayatti, P. S. 
Effect of pyridoxamine on chemical modification of proteins by carbonyls in 
diabetic rats: Characterization of a major product from the reaction of 
pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402:110-119; 2002. 
[195] Stitt, A.; Gardiner, T. A.; Alderson, N. L.; Canning, P.; Frizzell, N.; Duffy, N.; Boyle, C.; 
Januszewski, A. S.; Chachich, M.; Baynes, J. W.; Thorpe, S. R. The AGE inhibitor 
pyridoxamine inhibits development of retinopathy in experimental diabetes. 
Diabetes 51:2826-2832; 2002. 
[196] Monnier, V. M. Bacterial enzymes that can deglycate glucose- and fructose-modified 
lysine. Biochem. J.392:e1-3; 2005. 
[197] Horiuchi, T.; Kurokawa, T.; Saito, N. Purification and properties of fructosylamino acid 
oxidase from corynebacterium sp. 2-4-1. Agri Biol Chem 53:103-110; 1989. 
[198] Horiuchi, T.; Kurokawa, T. Purification and properties of fructosylamine oxidase from 
aspergillus sp. 1005. Agri Biol Chem 55:333-338; 1991. 
[199] Wiame, E.; Delpierre, G.; Collard, F.; Van Schaftingen, E. Identification of a pathway 
for the utilization of the amadori product fructoselysine in escherichia coli. J. Biol. 
Chem. 277:42523-42529; 2002. 
[200] Wiame, E.; Van Schaftingen, E. Fructoselysine 3-epimerase, an enzyme involved in the 
metabolism of the unusual amadori compound psicoselysine in escherichia coli. 
Biochem. J.378:1047-1052; 2004. 
[201] Wiame, E.; Lamosa, P.; Santos, H.; Van Schaftingen, E. Identification of glucoselysine-
6-phosphate deglycase, an enzyme involved in the metabolism of the fructation 
product glucoselysine. Biochem. J. 392:263-269; 2005. 
[202] Rahbar, S.; Kumar Yernini, K.; Scott, S.; Gonzales, N.; Lalezari, I. Novel inhibitors of 
advanced glycation endproducts. Biochem. Biophys. Res. Commun. 262:651-656; 1999. 
[203] Rahbar, S.; Yerneni, K. K.; Scott, S.; Gonzales, N.; Lalezari, I. Novel inhibitors of 
advanced glycation endproducts (part II). Mol. Cell Biol. Res. Commun. 3:360-366; 
2000. 
[204] Ulrich, P.; Zhang, X. Pharmacological reversal of advanced glycation end-product-
mediated protein crosslinking. Diabetologia 40 Suppl 2:S157-9; 1997. 
[205] Wolffenbuttel, B. H.; Boulanger, C. M.; Crijns, F. R.; Huijberts, M. S.; Poitevin, P.; 
Swennen, G. N.; Vasan, S.; Egan, J. J.; Ulrich, P.; Cerami, A.; Levy, B. I. Breakers of 
advanced glycation end products restore large artery properties in experimental 
diabetes. Proc. Natl. Acad. Sci. U. S. A. 95:4630-4634; 1998. 
www.intechopen.com
 Pharmacology 
 
708 
[206] Guo, Y.; Lu, M.; Qian, J.; Cheng, Y. L. Alagebrium chloride protects the heart against 
oxidative stress in aging rats. J. Gerontol. A Biol. Sci. Med. Sci. 2009. 
[207] Vaitkevicius, P. V.; Lane, M.; Spurgeon, H.; Ingram, D. K.; Roth, G. S.; Egan, J. J.; 
Vasan, S.; Wagle, D. R.; Ulrich, P.; Brines, M.; Wuerth, J. P.; Cerami, A.; Lakatta, E. 
G. A cross-link breaker has sustained effects on arterial and ventricular properties 
in older rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 98:1171-1175; 2001. 
[208] Kass, D. A.; Shapiro, E. P.; Kawaguchi, M.; Capriotti, A. R.; Scuteri, A.; deGroof, R. C.; 
Lakatta, E. G. Improved arterial compliance by a novel advanced glycation end-
product crosslink breaker. Circulation 104:1464-1470; 2001. 
[209] Zieman, S. J.; Melenovsky, V.; Clattenburg, L.; Corretti, M. C.; Capriotti, A.; 
Gerstenblith, G.; Kass, D. A. Advanced glycation endproduct crosslink breaker 
(alagebrium) improves endothelial function in patients with isolated systolic 
hypertension. J. Hypertens. 25:577-583; 2007. 
[210] Little, W. C.; Zile, M. R.; Kitzman, D. W.; Hundley, W. G.; O'Brien, T. X.; Degroof, R. C. 
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in 
the treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11:191-195; 
2005. 
[211] Bakris, G. L.; Bank, A. J.; Kass, D. A.; Neutel, J. M.; Preston, R. A.; Oparil, S. Advanced 
glycation end-product cross-link breakers. A novel approach to cardiovascular 
pathologies related to the aging process. Am. J. Hypertens. 17:23S-30S; 2004. 
[212] Hartog, J. W.; Willemsen, S.; van Veldhuisen, D. J.; Posma, J. L.; van Wijk, L. M.; 
Hummel, Y. M.; Hillege, H. L.; Voors, A. A.; for the BENEFICIAL investigators. 
Effects of alagebrium, an advanced glycation endproduct breaker, on exercise 
tolerance and cardiac function in patients with chronic heart failure. Eur. J. Heart 
Fail. 13:899-908; 2011. 
[213] Krautwald, M.; Leech, D.; Horne, S.; Steele, M. L.; Forbes, J.; Rahmadi, A.; Griffith, R.; 
Munch, G. The advanced glycation end product-lowering agent ALT-711 is a low-
affinity inhibitor of thiamine diphosphokinase. Rejuvenation Res. 14:383-391; 2011. 
www.intechopen.com
Pharmacology
Edited by Dr. Luca Gallelli
ISBN 978-953-51-0222-9
Hard cover, 720 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The history of pharmacology travels together to history of scientific method and the latest frontiers of
pharmacology open a new world in the search of drugs. New technologies and continuing progress in the field
of pharmacology has also changed radically the way of designing a new drug. In fact, modern drug discovery
is based on deep knowledge of the disease and of both cellular and molecular mechanisms involved in its
development. The purpose of this book was to give a new idea from the beginning of the pharmacology,
starting from pharmacodynamic and reaching the new field of pharmacogenetic and ethnopharmacology.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Indu Dhar and Kaushik Desai (2012). Aging: Drugs to Eliminate Methylglyoxal, a Reactive Glucose Metabolite,
and Advanced Glycation Endproducts, Pharmacology, Dr. Luca Gallelli (Ed.), ISBN: 978-953-51-0222-9,
InTech, Available from: http://www.intechopen.com/books/pharmacology/aging-drugs-to-eliminate-
methylglyoxal-a-reactive-glucose-metabolite-and-advanced-glycation-endprodu
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
